HideChilds = False
SystemName = Homepage

Bioverativ – Science matters. Because patients matter.

Science matters.
Because patients matter.

Learn more

Science that redefines what's possible

Our scientists brought the first major advances in hemophilia treatment in nearly two decades, and we’re committed to developing new, life-changing medicines for people with rare blood disorders.

Learn more

Expanding access around the world

We committed, with Sobi, to donate up to 1 billion IUs of factor therapy to the developing world. Already, more than 12,300 people with hemophilia have been treated.

Learn more

Bioverativ in the news

Monday, October 2, 2017 7:30 AM

Sangamo and Bioverativ Announce FDA Acceptance of IND Application for ST-400 – a Gene-Edited Cell Therapy Candidate – to Treat Beta-Thalassemia

Read more